Astellas trumpets rapid growth as it moves into $150M U.S. campus

Astellas opened its gleaming new $150 million North American headquarters in the Chicago area on Monday, staking its claim as a big player in the U.S. biopharma industry. The company erected two seven-story towers at the corporate campus, totaling 425,000 square feet. And the pharma company left room for a third tower to accomodate future growth.

The Chicago Tribune notes that Astellas has been on a recruitment drive in recent months, adding 284 staffers to its U.S. roster. Another 90 new hires are planned. Astellas relocated its headquarters with the help of Illinois officials, who chipped in about $4 million worth of incentives to claim the bragging rights for the new facility.

Astellas has been growing its pipeline for urological drugs recently. And it made a $4 billion bet on adding new cancer drugs when it acquired OSI for $4 billion back in 2010.

- here's the story from The Chicago Tribune

Related Articles:
Astellas, biotech VCs to pump $14M into virtual drug developer
Astellas scores highest in Japanese M&A bout
Astellas buys OSI for $4B

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.